- Dzik, W. H. (2006). “The NHLBI
Clinical Trials Network in transfusion
medicine and hemostasis: an overview.”
Journal of Clinical Apheresis;
21:57-59.
|
- George, J. N; Woodson, R. D; Kiss, J.
E; Kojouri, K.; Vesely, S. K (2006). “Rituximab
therapy for thrombotic thrombocytopenic
purpura: a proposed study of the Transfusion
Medicine/Hemostasis Clinical Trials Network
with a systematic review of rituximab
therapy for immune-mediated disorders.”
Journal of Clinical Apheresis;
21:49-56.
|
- Journeycake, J; Brambilla D; Ragni M.
(2005). “Central venous access device-related
infections in hemophilia (abstract).”
Blood; 106: 898A.
|
- Konkle, B. A. and Nemo, G. J. (2005).
"Defining effective therapies in
transfusion medicine and hemostasis: new
opportunities with the TMH Network."
Transfusion; 45(9): 1404-6.
|
- Segal, J. B. and Dzik, W. H. (2005).
"Paucity of studies to support that
abnormal coagulation test results predict
bleeding in the setting of invasive procedures:
an evidence-based review." Transfusion;
45(9): 1413-25.
|
- Slichter, S. J. (2006). “Background,
rationale, and design of a clinical trial
to assess the effects of platelet dose
on bleeding risk in thrombocytopenic patients.”
Journal of Clinical Apheresis;
21:78-84.
|
- Steiner, M. E; Key N.S; Levy J. H; (2005).
"Activated recombinant factor VII
in cardiac surgery." Current Opinion
in Anaesthesiology; 18(1): 89-92.
|
- Giulino, L.B.; Bussel J.B.; Neufeld, E.J.;
Pediatric Immunology Committees of the TMH Clinical Trial Network;
(2007). "Treatment with rituximab in benign and malignant hematologic
disorders in children." Journal of Pediatrics; 150(4): 339-44.
|
- Hiller, C.D.; Blumber, N; Glynn, S.A.; Ness, P.M.; NHLBI Working Group in
Transfusion Recipient Epidemiology and Outcomes Research; (2008).
"Transfusion recipient epidemiology and outcomes research: possibilities
for the future." Transfusion; 48(8): 1530-7.
|
- Ragni M.V.; Journeycake J.M.; Brambilla D.J.; (2008) "Tissue plasminogen
activator to prevent central venous access device infections: a systematic review
of central venous access catheter thrombosis, infection and thromboprophylaxis."
Haemophilia; 14:30-38.
|
- Slichter S.J.; Kaufman R.M.; Assmann S.F.; Brecher M.E.; Gernsheimer T.; Hillyer C.D.;
McCullough J.; Strauss R.G.; and Triulzi D.; (2008) "Effects of Prophylactic
Platelet (Plt) Dose on Transfusion (Tx) Outcomes (PLADO Trial)" Blood: 112:111.
|
- Josephson C.; Sloan S.; Granger S.; et al. (2009) "Increased incidence of Grand 2
and higher bleeding in pediatric PLADO trial patients." Transfusion: 49:19A-20A.
|
- Slichter S.J.; Kaufman R.M.; Assmann S.F.; et al; (2010). "Dose of prophylactic platelet
transfusions and prevention of hemorrhage." New England Journal of Medicine:
362(7):600-13.
|
- Slichter S.J.; Triulzi D.J.; Assmann S.F.; (2010) "Prophylactic platelet transfusions."
New England Journal of Medicine: 362:2142.
|
- Triulzi D.J.; Assmann S.; Strauss R.G.; et al. (2009) "Characteristics of transfused
platelets do not affect bleeding outcomes in hypoproliferative thrombocytopenia."
Blood: 114:14-14.
|
- Steiner M.E.; Assmann S.F.; Levy J.H.; Marshall J.; Pulkrabek S.; Sloan S.R.; Triulzi D. J.;
Stowell C.P.; (2010) "Addressing the question of the effect of RBC Storage on Clinical Outcomes:
The Red Cell Storage Duration Study (RECESS) (Section 7)." Transfus. Apher. Sci. Aug; 43(1):107-16.
|
- Lehmann H.P.; Dambita N.; Buchanan G.R.; Casella J.F.; (2011) "Decision modeling of
disagreements: Pediatric Hematologists' Management of Idiopathic Thrombocytopenic Purpora."
Medical Decision Making. Mar 14.
|
